Xvivo Perfusion ABXVIPF -1.32%91 1-Year Share Buyback Ratio is 0.00 as of Mar. 2026. GuruFocus rates XVIPF with a GF Score™ of 91/100 and a GF Value™ of $41.74 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 540 Medical Devices & Instruments companies, Xvivo Perfusion AB ranks worse than 185185% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Xvivo Perfusion AB's current 1-Year Share Buyback Ratio was 0.00%.
XVIPF's 1-Year Share Buyback Ratio is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: -2.85 * Ranked among companies with meaningful 1-Year Share Buyback Ratio only.
Xvivo Perfusion AB (OTCPK:XVIPF) 1-Year Share Buyback Ratio Explanation
A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Xvivo Perfusion AB 1-Year Share Buyback Ratio Related Terms
XVIPF vs ABT, SYK, MDT: 1-Year Share Buyback Ratio Comparison
For the Medical Devices subindustry, Xvivo Perfusion AB's 1-Year Share Buyback Ratio, along with its competitors' market caps and 1-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xvivo Perfusion AB 1-Year Share Buyback Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's 1-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Xvivo Perfusion AB's 1-Year Share Buyback Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a 1-Year Share Buyback Ratio of 0.00 mean?
Xvivo Perfusion AB (XVIPF) has a 1-Year Share Buyback Ratio of 0.00 as of Mar. 2026. The 1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. View historical data for Xvivo Perfusion AB and its competitors. According to the industry distribution chart, Xvivo Perfusion AB ranks #999999 out of 540 companies in the Medical Devices & Instruments industry.
Is Xvivo Perfusion AB's 1-Year Share Buyback Ratio too high?
Xvivo Perfusion AB's current 1-Year Share Buyback Ratio is 0.00. Based on the distribution chart, Xvivo Perfusion AB ranks #999999 out of 540 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Xvivo Perfusion AB has a GF Score™ of 91/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's 1-Year Share Buyback Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Xvivo Perfusion AB ranks #999999 out of 540 companies for 1-Year Share Buyback Ratio. This places Xvivo Perfusion AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Share Buyback Ratio for a Medical Devices & Instruments company?
A good 1-Year Share Buyback Ratio depends on the Medical Devices & Instruments industry context. However, 1-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Share Buyback Ratio mean?
A high 1-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. View historical data for Xvivo Perfusion AB and its competitors. Xvivo Perfusion AB's current 1-Year Share Buyback Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (XVIPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $41.74, compared to a current price of $29.00 — trading 30.5% below its estimated fair value. The current 1-Year Share Buyback Ratio is 0.00. Xvivo Perfusion AB's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Share Buyback Ratio calculated?
1-Year Share Buyback Ratio is calculated from a company's financial statements. For Xvivo Perfusion AB (XVIPF), the current 1-Year Share Buyback Ratio is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xvivo Perfusion AB (XVIPF) Overvalued in 2026?
Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued.
The current stock price of $29.00 is trading 30.5% below its estimated GF Value™ of $41.74.
GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.
Key valuation signals for XVIPF:
1-Year Share Buyback Ratio: 0.00
GF Value™: $41.74 vs. price of $29.00 (30.5% below fair value)
No single metric tells the full story. See the XVIPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
91GF Score
Get the complete analysis for XVIPF
1-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XVIPF has been successfully added to your 